Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16083084 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNADPP4DPP7YAP1 | |
| SCHEMBL16083090 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNADPP4DPP7YAP1 | |
| SCHEMBL5564424 | 0.87 | ALDH1A1 (0.67) | ALDH1A1LMNADPP4DPP7YAP1 | |
| SCHEMBL23144513 | 0.86 | ALDH1A1 (0.59) | ALDH1A1LMNADPP4DPP7CHRM2 | |
| SCHEMBL16082804 | 0.82 | — | — | |
| SCHEMBL1712955 | 0.81 | DPP4 (0.49) | ALDH1A1LMNADPP4DPP7CHRM2 | |
| SCHEMBL1712954 | 0.81 | DPP4 (0.45) | ALDH1A1LMNADPP4DPP7CHRM2 | |
| SCHEMBL13665501 | 0.81 | DPP4 (0.49) | ALDH1A1LMNADPP4DPP7CHRM2 | |
| SCHEMBL23144568 | 0.80 | ALDH1A1 (0.58) | ALDH1A1LMNAYAP1TEAD4CHRM2 | |
| SCHEMBL13974450 | 0.79 | DPP7 (0.51) | ALDH1A1DPP4DPP7CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801328-B | Autotaxin inhibitors and uses thereof | 四川海思科制药有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-11618750-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-01-26 | — | — | US | disclosed |
| EP-3983075-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| CN-113993868-A | Substituted pyrazolopyridinamides and their use as modulators of the GLUN2B receptor | 詹森药业有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11072611-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2021-07-27 | — | — | US | disclosed |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| EP-2970255-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-08-02 | — | — | EP | disclosed |
| US-9670204-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2017-06-06 | — | — | US | disclosed |
| EP-3010922-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| EP-3010922-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160244443-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-08-25 | — | — | US | disclosed |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9249141-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20150111872-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-04-23 | — | — | US | disclosed |
| US-8993590-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2015-03-31 | — | — | US | disclosed |
| US-20140303140-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244443-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | ALDH1A1 4668/4885LMNA 3277/4885DPP4 2495/4885 |
| US-11072611-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | ENPP2, PRXL2A, TPX2 | ALDH1A1 4620/4885LMNA 3035/4885DPP4 2592/4885 |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | ALDH1A1 4707/4885LMNA 3380/4885DPP4 2276/4885 |
| US-20150111872-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | ALDH1A1 4668/4885LMNA 3277/4885DPP4 2495/4885 |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2278/4885LMNA 3981/4885DPP4 1826/4885 |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | ALDH1A1 4668/4885LMNA 3277/4885DPP4 2495/4885 |
| US-20140303140-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | ALDH1A1 4668/4885LMNA 3277/4885DPP4 2495/4885 |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ALDH1A1 4716/4885LMNA 1189/4885DPP4 851/4885 |
| US-11618750-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2437/4885LMNA 4092/4885DPP4 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.